Insider Spends US$395k Buying More Shares In Relmada Therapeutics [Yahoo! Finance]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Yahoo! Finance
NASDAQ:RLMD ) shareholders may wish to note that the CEO & Director, Sergio Traversa, recently bought US$395k worth of stock, paying US$2.82 for each share. That certainly has us anticipating the best, especially since they thusly increased their own holding by 57%, potentially signalling some real optimism. Relmada Therapeutics Insider Transactions Over The Last Year In fact, the recent purchase by Sergio Traversa was the biggest purchase of Relmada Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of US$3.27. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. Happily, the Relmada Therapeutics insiders decided to buy shares at close to current prices. Relmada Therapeutics insiders may have
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024GlobeNewswire
- Relmada Therapeutics, Inc. (NASDAQ: RLMD) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock, up previously from $3.50.MarketBeat
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmPR Newswire
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmGlobeNewswire
- Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 8/7/24 - Beat
RLMD
Sec Filings
- 10/23/24 - Form 4
- 9/13/24 - Form EFFECT
- 9/11/24 - Form 4
- RLMD's page on the SEC website